Listen to the article
Federal health officials on Tuesday issued a warning against biotech billionaire Dr. Patrick Soon-Shiong for making misleading claims about his company’s bladder cancer drug, suggesting it could treat or even cure multiple types of cancers.
The Food and Drug Administration’s warning letter addressed statements made by Soon-Shiong during a January episode of “The Sean Spicer Show” podcast, where he described his company’s drug, Anktiva, as “the most important molecule that could cure cancer” and claimed “it actually can treat all cancers.” He further asserted, “We have the therapy to prevent cancer if you were exposed to radiation, and that’s Anktiva.”
FDA regulators determined these statements violated federal drug marketing regulations by creating a “misleading impression” of the medication’s capabilities. The agency also cited issues with a television advertisement that, like the podcast, referred to Anktiva as a “cancer vaccine,” which the FDA deemed false.
Anktiva, the flagship product of ImmunityBio Inc., received FDA approval in 2024 specifically for patients with a difficult-to-treat form of bladder cancer. While the company has been pursuing regulatory approval to expand the drug’s applications to other conditions, including lung and pancreatic cancer, the current approval remains limited to bladder cancer only.
The regulatory warning triggered an immediate market response, with ImmunityBio shares dropping more than 21% in Tuesday’s trading to close at $7.42.
Soon-Shiong, who owns the Los Angeles Times and serves as ImmunityBio’s executive chairman and chief medical officer, has built a reputation as a healthcare entrepreneur through acquiring several biotech firms. His public statements about Anktiva’s capabilities extend far beyond its approved use, putting his company at odds with strict FDA marketing regulations.
The agency’s warning letter, addressed to ImmunityBio CEO Richard Adcock, also noted that the podcast discussion failed to mention any of the drug’s known side effects, which can include urinary tract infections, pain, chills, and pyrexia (fever). Federal law requires pharmaceutical promotions to provide balanced information about both a drug’s benefits and risks.
By Tuesday afternoon, ImmunityBio had removed the link to the podcast from its company website. The FDA has given the California-based firm 15 days to correct the issues and submit a written response outlining its compliance plans.
Company spokesperson Sarah Singleton acknowledged the warning in an email statement, saying ImmunityBio takes the FDA’s concerns “very seriously” and intends to “work cooperatively with the agency to address the matters raised in the letter.”
This action reflects the FDA’s intensified scrutiny of pharmaceutical marketing practices under the current administration. The agency has increased enforcement against misleading drug promotions by companies and executives, particularly targeting statements made on television programs and podcasts.
The incident highlights the tension between biotechnology innovation and regulatory compliance in the pharmaceutical industry. While companies like ImmunityBio work to develop treatments for difficult-to-treat cancers, the FDA maintains strict guidelines about how these treatments can be marketed to protect patients and ensure claims are supported by scientific evidence.
For patients with cancer and healthcare providers, the distinction between approved treatments and unverified claims remains critical for making informed medical decisions. The FDA’s warning serves as a reminder that even high-profile executives must adhere to established regulatory frameworks when discussing their products’ capabilities.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
8 Comments
While I’m hopeful for new cancer treatments, the FDA is right to call out these dubious marketing claims. Patients need reliable information, not exaggerated promises, when facing such a devastating disease.
I’m glad the FDA is taking action against these misleading claims. Patients facing cancer need accurate information to make informed decisions, not exaggerated promises from company executives.
This is a concerning example of a powerful biotech executive seemingly prioritizing profits over patient welfare. The FDA is right to intervene and ensure cancer drug marketing adheres to the facts.
It’s disappointing to see a respected medical professional making such bold, unsubstantiated claims about a cancer drug. The FDA’s action highlights the need for rigorous scientific scrutiny, even for high-profile individuals.
The FDA’s warning highlights the importance of rigorous scientific scrutiny and regulatory oversight, even for high-profile companies and individuals. Patients should be wary of exaggerated marketing claims about cancer treatments.
It’s troubling to see a billionaire biotech executive making such bold and unsubstantiated claims about their drug’s abilities. The FDA is correct to enforce truthful advertising standards, especially for serious conditions like cancer.
Claiming a drug can ‘cure all cancers’ seems like a huge stretch. While I want to see medical breakthroughs, the FDA is right to crack down on misleading statements that could give false hope to vulnerable patients.
Misleading claims about cancer treatments are very concerning. The FDA is right to take action against these exaggerated marketing statements. Patients deserve accurate information about approved uses and capabilities of drugs.